Frustrated by the limitations of commercially available biomarkers — researchers led by The University of Manchester’s Professor Paul Townsend and senior author of the resulting paper, and honorary professor at Manchester, Professor Vassilis Gorgoulis, have developed a universally applicable method to assess senescence across biomedicine, from cancer research to gerontology.
Cellular senescence is a fundamental biological process involved in every day embryonic and adult life, both good — for normal human development — and, more importantly to researchers, dangerous by triggering disease conditions. Up to now available senescence detecting biomarkers have very limited and burdensome application. Therefore, a more effective, precise and easy-to-use biomarker would have considerable benefits for research and clinical practice.
“The method we have developed provides unprecedented advantages over any other available senescence detection products — it is straight-forward, sensitive, specific and widely applicable, even by non-experienced users,” said Professor Townsend.
“In addition to helping researchers make significant new breakthroughs into the causes of diseases — including cancer — through more effective understanding of senescence in cells, the new process will also aid the impact of emerging cellular rejuvenation therapies.
“By the better identification — and subsequently elimination of — senescent cells, tissues can be rejuvenated and the health span extended.”
The research on the new methodology — published as ‘Robust, universal biomarker to detect senescent cells in biological specimens’ in the journal Ageing Cell — has led to two pending UK patents.